MAPT and Lewy body dementia: Using a cohort of DLB subjects, we stratified patients based on mass-spectrometry measurement of insoluble tau abundance, irrespective of pathology findings or Braak staging, which traditionally rely on specific tau antibodies targeting certain modifications and may not fully quantify total tau expression [19].